Moving averages
SMA 200$0.51-43.35%
Company profile
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
SectorHealthcare
IndustryBiotechnology
Market cap$10.67M
P/E ratioNone
EPS$-6.46
Beta0.903
Dividend yield0.00%
52-week high$1.53
52-week low$0.26
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 52
VRTX
Vertex Pharmaceuticals Inc
RSI 64
CRSP
CRISPR Therapeutics AG
RSI 54
IOVA
Iovance Biotherapeutics Inc
RSI 66
MRNA
Moderna Inc
RSI 67
VKTX
Viking Therapeutics Inc
RSI 49
SRPT
Sarepta Therapeutics Inc
RSI 67
EDIT
Editas Medicine Inc
RSI 52
NVAX
Novavax Inc
RSI 72
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 44
RSI alerts for GTBP
Get an email the moment GT Biopharma Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 16 August 2026 at 2:31 AM EDT